An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Aspergerls Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Trial Profile

An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Aspergerls Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Memantine (Primary)
  • Indications Asperger syndrome; Autistic disorder; Pervasive child development disorders
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 01 Jul 2013 Planned End Date changed from 1 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 01 Jun 2013 Planned number of patients changed from 850 to 900 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top